NEWSROOM

 

FOR MORE INFORMATION, CONTACT:                                                                                                                                     
Mark Stultz
1-612-770-0390
info@deepbraininnovations.com
                                                                       

May 23 2013 - NDI LAUNCHES DEEP BRAIN INNOVATIONS, LLC
Optimizing electrical stimulation to treat Parkinson's disease and other neurological conditions

CLEVELAND, OH and DURHAM, NC – NDI Medical, LLC, a venture and commercialization firm that funds
and develops innovative neurodevice technologies, has launched its next portfolio company, Deep Brain
Innovations, LLC (DBI). DBI will commercialize its groundbreaking technology that is designed to optimize
deep brain stimulation (DBS) therapy for patients with Parkinson's disease. Currently available DBS therapy is
effective in treating Parkinson's disease and generates more than $275 million in annual sales. However, NDI
has validated an opportunity to further expand this market with a revolutionary approach to DBS.

DBI's proprietary Temporally Optimized Patterned Stimulation (TOPS™) technology is based on the
seminal research of Dr. Warren Grill, the Addy Professor of Biomedical Engineering at Duke University. "After
more than a decade of research we've discovered a way to 'speak' to the area of the brain that controls
movement in persons with Parkinson's disease. The stimulation patterns, somewhat akin to Morse code for the
brain, were designed to be much more efficient than conventional DBS" said Grill. "This is vital because the
gains we make in improved efficiency increase the longevity of implanted brain stimulation devices, thus
reducing health care costs, risks, and complications associated with frequent battery replacement for persons
with DBS Systems."

Dr. Grill, Chief Scientific Officer, and Geoff Thrope, CEO and veteran neurodevice entrepreneur,
founded DBI on the basis of NDI's model, which is to invest in and develop technologies in large markets
where there is at least one validated product, but where critical needs still exist. Thrope and Grill previously
sold their proprietary MEDSTIM system for the treatment of urinary incontinence to Medtronic, Inc. for $42
million, which followed this same successful model.

There have been more than 80,000 DBS surgeries completed since 1997, using conventional DBS
technology that target specific areas of the brain to reduce the symptoms of Parkinson's disease. Parkinson's
disease currently affects more than 6.3 million people, with 60,000 new cases diagnosed annually in the U.S.

Dr. Grill's lab in Duke's Pratt School of Engineering combined unique computer models and engineering
methods to design novel patterns of stimulation to be much more energy efficient than the conventional DBS
systems currently used to treat Parkinson's disease. DBI's innovative TOPS™ technology has been evaluated
in a series of clinical studies with neurosurgical advisors and DBS thought leaders at Duke University Medical
Center, Emory University, and Wake Forest Baptist Medical Center in patients undergoing replacement of their
implanted device following battery depletion. Perhaps as exciting is the prospect of using DBI's TOPS™
technology to enhance the effectiveness of the therapeutic treatment and expand it to other indications.

"We will be seeking strategic partners to integrate our TOPS™ technology into their devices to develop
what we expect will be the smallest and longest lasting DBS systems available." said Thrope. "In addition to
treating Parkinson's disease, we can also adapt our technology to other disease states being investigated for
treatment with DBS such as Alzheimer's disease, depression, epilepsy, obsessive-compulsive disorder, and
obesity."

About DBI
Deep Brain Innovations™ (DBI) is a medical device company that has developed a proprietary method to
optimize DBS therapy through novel patterns of stimulation. DBI's Temporally Optimized Patterned
Stimulation™ (TOPS) technology will increase the efficiency of implanted neurostimulation systems. TOPS™
technology allows the development of devices that are designed to be more cost-effective, smaller, and longer
lasting, requiring fewer lifetime replacements and reducing the potential for infection and other complications.
DBI was formed in 2012 as a portfolio company of NDI Medical, LLC. For more information, visit,
www.deepbraininnovations.com.

About NDI
Founded in 2002, NDI is a hybrid venture capital and commercialization firm, and the only one focusing
exclusively on innovative neurodevice technologies that address unmet needs with potential to provide
significant returns to its investors. NDI is headquartered in Cleveland, Ohio with locations in North Carolina's
Research Triangle and Minneapolis, Minnesota. For more information, visit www.ndimedical.com.